Aurobindo Pharma Ltd.
AUROPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,552.6.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%9.9%
- ✓Low debt (D/E < 0.5)0.21x
- ✓Positive free cash flow
- ✕Revenue growth > 10%6%
- ✓Earnings growing2%
- ✓Net margin ≥ 10%10.4%
- ✓Current ratio > 1.51.81
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 3.96
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 3.96.
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~38% below our estimated fair value.
About Aurobindo Pharma Ltd.
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastr
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.